---
schema_version: "secwatch.filing_event.v1"
accession: "0001847903-22-000071"
form_type: "8-K"
ticker: "CNTA"
cik: "0001847903"
company_name: "Centessa Pharmaceuticals plc"
filed_at: "2022-10-14T23:59:59+00:00"
generated_at: "2026-06-23T03:37:58.499432+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Centessa CMO Javad Shahidi departs; Antoine Yver assumes responsibilities effective Oct 14, 2022

## Summary
- CMO Javad Shahidi mutually agreed to depart; last day Oct 14, 2022.
- Departure not due to any disagreement regarding operations, policies, or practices.
- Chairman of Development Antoine Yver (30+ yrs drug dev) assumes all CMO responsibilities effective Oct 14.
- Dr. Yver led approvals for 11 drugs including Tagrisso, Lynparza, Enhertu; prior roles at Daiichi Sankyo and AstraZeneca.

## SEC filing metadata
- accession: 0001847903-22-000071
- form_type: 8-K
- ticker: CNTA
- cik: 0001847903
- company_name: Centessa Pharmaceuticals plc
- filed_at: 2022-10-14T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847903/000184790322000071/0001847903-22-000071-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847903/000184790322000071/cnta-20221013.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001847903-22-000071
- JSON: https://secwatch.observer/filing/0001847903-22-000071.json
- Plain text: https://secwatch.observer/filing/0001847903-22-000071.txt

## Key facts
- Executive change
  Antoine Yver changed role as Chief Medical Officer at Centessa Pharmaceuticals plc.
  - Action: assumed responsibilities
  - Role: Chief Medical Officer
  source text: Antoine Yver, M.D., M.Sc., Chairman of Development of the Company, will assume all responsibilities currently held by Dr. Shahidi effective October 14, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1847903/000184790322000071/0001847903-22-000071-index.htm
- Executive change
  Javad Shahidi departed as Chief Medical Officer at Centessa Pharmaceuticals plc.
  - Action: mutually agreed to depart
  - Role: Chief Medical Officer
  source text: On October 13, 2022, Centessa Pharmaceuticals plc (the “Company”) and Javad Shahidi, M.D., M.Sc., Chief Medical Officer, mutually agreed that Dr. Shahidi will be departing from the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1847903/000184790322000071/0001847903-22-000071-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.